Tae Won Kim

17.2k total citations · 3 hit papers
296 papers, 7.5k citations indexed

About

Tae Won Kim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Tae Won Kim has authored 296 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 226 papers in Oncology, 110 papers in Pulmonary and Respiratory Medicine and 66 papers in Pathology and Forensic Medicine. Recurrent topics in Tae Won Kim's work include Colorectal Cancer Treatments and Studies (170 papers), Gastric Cancer Management and Outcomes (66 papers) and Genetic factors in colorectal cancer (59 papers). Tae Won Kim is often cited by papers focused on Colorectal Cancer Treatments and Studies (170 papers), Gastric Cancer Management and Outcomes (66 papers) and Genetic factors in colorectal cancer (59 papers). Tae Won Kim collaborates with scholars based in South Korea, United States and Japan. Tae Won Kim's co-authors include Yong Sang Hong, Jae‐Lyun Lee, Yoon‐Koo Kang, Min‐Hee Ryu, Chang Sik Yu, Jin Cheon Kim, Heung Moon Chang, Jong Hoon Kim, Takayuki Yoshino and Se Jin Jang and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Tae Won Kim

287 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

2015 652 citations Takayuki Yoshino, Rocio García‐Carbonero et al. profile →
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

2014 339 citations Timothy Price, Marc Peeters et al. profile →
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial

2025 34 citations Takayuki Yoshino, Tae Won Kim et al. Nature Medicine profile →

Peers

Countries citing papers authored by Tae Won Kim

Since Specialization

Citations

This map shows the geographic impact of Tae Won Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tae Won Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tae Won Kim more than expected).

Fields of papers citing papers by Tae Won Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tae Won Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tae Won Kim. The network helps show where Tae Won Kim may publish in the future.

Co-authorship network of co-authors of Tae Won Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Tae Won Kim. A scholar is included among the top collaborators of Tae Won Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tae Won Kim. Tae Won Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer 2025 ·Journal of Clinical Oncology ·Filippo Pietrantonio, Lisa Salvatore, Taito Esaki, Dominik Paul Modest, D. Páez López-Bravo, Julien Taı̈eb, Michalis V. Karamouzis, Erika Ruíz‐García, Tae Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun‐Huei Yeh, Emily Chan, Joseph Chao, Qui Tran, Chiara Cremolini, Marwan Fakih	7
2	Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study 2024 ·European Journal of Cancer ·Atsuo Takashima, Pilar García‐Alfonso, (unknown), Ali Ayberk Beşen, Yong Sang Hong, Pieter‐Jan Cuyle, Patricio Yañez, Matthew Burge, Takayuki Yoshino, Tae Won Kim, Karen Cui, (unknown), Rishi Jain, David E. Adelberg, Julien Taı̈eb	7
3	Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial 2024 ·Nature Medicine ·Hyung‐Don Kim, (unknown), Ho Yeong Lim, Baek‐Yeol Ryoo, Min‐Hee Ryu, (unknown), Hong Jae Chon, Beodeul Kang, Jung Yong Hong, Han Chu Lee, Deok‐Bog Moon, Ki‐Hun Kim, Tae Won Kim, David Tai, Valerie Chew, Jeong Seok Lee, Richard S. Finn, June‐Young Koh, Changhoon Yoo	29
4	CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer 2023 ·Scientific Reports ·Sora Kang, Sun Young Kim, Yong Sang Hong, Tae Won Kim, (unknown), Min Jung Kim, Jeong Eun Kim	1
5	Prospective, open‐label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study 2023 ·Asia-Pacific Journal of Clinical Oncology ·Tsai‐Sheng Yang, Hong‐Hwa Chen, (unknown), Tae Won Kim, Jong Gwang Kim, Joong Bae Ahn, (unknown), Johnson Lin, Gwo Fuang Ho, (unknown), Sally Temraz, Matthew Burge, Clarinda Chua, (unknown), Young Suk Park	0
6	LBA32 Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study 2023 ·Annals of Oncology ·(unknown), Thierry André, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, C.J.A. Punt, Denis Smith, Rocio García‐Carbonero, Julia Alcaide, Peter Gibbs, Christelle de la Fouchardière, Fernando Rivera, (unknown), Dung T. Le, Takayuki Yoshino, Yu Zuo, (unknown), David E. Adelberg, Luis A. Díaz	12
7	Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis 2023 ·ESMO Open ·Jaewon Hyung, (unknown), (unknown), Shinkyo Yoon, Changhoon Yoo, Yong Sang Hong, Jae Ho Jeong, Tae Won Kim, Seong Woo Jeon, (unknown), Chan Kwon Jung, (unknown), Ji Hoon Kim, Sail Chun, Jin‐Hee Ahn	2
8	Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103) 2023 ·The Journal of Clinical Pharmacology ·Elena Garralda, Do Youn Oh, Antoîne Italiano, Philippe L. Bédard, Jean‐Pierre Delord, Emiliano Calvo, Patricia LoRusso, Zev A. Wainberg, Andrés Cervantes, Alejo Rodríguez‐Vida, Colby S. Shemesh, Rucha Sane, Diana Mendus, Hao Ding, Robert L. Hendricks, (unknown), Byoung Chul Cho, Tae Won Kim, Benjamin M. Wu	9
9	Whole-genome sequencing reveals an association between small genomic deletions and an increased risk of developing Parkinson’s disease 2023 ·Experimental & Molecular Medicine ·Ji‐Hye Oh, Sungyang Jo, Kye Won Park, Eun‐Jae Lee, Seung Hyun Lee, Yun Su Hwang, (unknown), (unknown), (unknown), Sung‐Min Chun, Chong Jai Kim, Tae Won Kim, Chang Ohk Sung, Sehyun Chae, Sun Ju Chung	6
10	Immuno-genomic classification of colorectal cancer organoids reveals cancer cells with intrinsic immunogenic properties associated with patient survival 2021 ·Journal of Experimental & Clinical Cancer Research ·Eun Jeong Cho, Minsuh Kim, (unknown), Jihye Kim, Ji‐Hye Oh, (unknown), (unknown), Deokhoon Kim, Sung‐Min Chun, Jihun Kim, (unknown), Tae Won Kim, Chang Sik Yu, Chang Ohk Sung, Se Jin Jang	23
11	Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G 2020 ·Cancers ·Hiroya Taniguchi, Takeharu Yamanaka, Daisuke Sakai, Kei Muro, Kentaro Yamazaki, Susumu Nakata, Hiroyuki Kimura, Paul Ruff, Tae Won Kim, Marc Peeters, Timothy Price	8
12	Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer 2018 ·Clinical Cancer Research ·Tae Won Kim, Marc Peeters, Anne Thomas, Peter Gibbs, (unknown), (unknown), Agnes Ang, Bruce Allen Bach, Timothy Price	41
13	Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPECCT Study 2018 ·Clinical Cancer Research ·Marc Peeters, Timothy Price, Michael Boedigheimer, Tae Won Kim, Paul Ruff, Peter Gibbs, Anne Thomas, Gaston Demonty, (unknown), Agnes Ang	32
14	Utilization of a Clinical Trial Management System for the Whole Clinical Trial Process as an Integrated Database: System Development 2018 ·Journal of Medical Internet Research ·Yu Rang Park, (unknown), (unknown), Soyoung Yoo, Chang‐Min Choi, (unknown), Tae Won Kim	21
15	[18F]fluorothymidine PET Informs the Synergistic Efficacy of Capecitabine and Trifluridine/Tipiracil in Colon Cancer 2017 ·Cancer Research ·(unknown), (unknown), (unknown), (unknown), Sang Ju Lee, Seung Jun Oh, Sun Young Chae, (unknown), Seung Jin Lee, Yong Sang Hong, Tae Won Kim, Dae Hyuk Moon	6
16	Knowledge and Perception about Clinical Research Shapes Behavior: Face to Face Survey in Korean General Public 2016 ·Journal of Korean Medical Science ·Yun Jung Choi, (unknown), (unknown), Soyoung Yoo, Seong Yoon Kim, Ji Sung Lee, Tal Burt, Tae Won Kim	16
17	Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity 2015 ·Molecular Cancer Therapeutics ·Jae‐Cheol Jo, (unknown), (unknown), (unknown), (unknown), Ha‐Reum Lee, (unknown), (unknown), Dae‐Hee Lee, (unknown), (unknown), Jeong Eun Kim, Kyu‐pyo Kim, Yong Sang Hong, Young‐Ah Suh, Se Jin Jang, (unknown), Jung Shin Lee, Dong‐Hoon Jin, Tae Won Kim	22
18	EFFECT OF FOOD AND DOSAGE ON CIMICOXIB PHARMACOKINETICS IN DOGS 2015 ·Medycyna Weterynaryjna ·Beata Łebkowska‐Wieruszewska, C. Kowalski, Tae Won Kim, Helen C. Owen, Hyo‐In Yun, Mario Gıorgı	1
19	MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation 2013 ·Cancer Research ·Jin Kyung Rho, Yun Jung Choi, Seon Ye Kim, Tae Won Kim, Eun Kyung Choi, Seon-Joo Yoon, (unknown), Eunhye Park, (unknown), Chang‐Min Choi, Jae Cheol Lee	120
20	Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II) 2012 ·Journal of Clinical Oncology ·Paulo M. Hoff, Andreas Hochhaus, Bernhard C. Pestalozzi, Niall C. Tebbutt, Jin Li, Tae Won Kim, Krassimir Koynov, G. Kurteva, Tamás Pintér, Ying Cheng, Brigitte Van Eyll, Laura A. Pike, Anitra Fielding, Jane Robertson, Mark Saunders	112

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact